- The FDA has granted Breakthrough Device Designation to Helius Medical Technologies Inc's HSDT PoNS device.
- Related content: Benzinga's Full FDA Calendar.
- The designation covers the device for use as a temporary treatment of dynamic gait and balance deficits due to stroke as an adjunct to a therapeutic exercise program in patients 22 years of age and over.
- PoNS, a portable neuromodulation stimulator, is a non-surgical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the tongue's surface to treat gait deficit.
- Price Action: HSDT shares are up 10.7% at $15.90 during the premarket session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
